Knee Osteoarthritis associated with Extra-Articular Deformity treated by Total Knee Arthroplasty plus simultaneous Corrective Osteotomy. / "Artrosis de rodilla asociada a deformidad extra-articular tratada mediante prótesis total de rodilla y osteotomía correctora de forma simultánea".

BACKGROUND: Correct mechanical limb alignment is crucial in Total Knee Arthroplasty (TKA) and is particularly difficult to achieve when the knee osteoarthritis (KOA) is associated with an Extra-Articular Deformity (EAD). Our objective is to present a surgical option in cases of severe knee arthritis associated with an EAD (indications, mechanical planning and surgical technique), pros and cons and discuss the results with this one-stage technique. METHODS: We retrospectively reviewed all cases of severe KOA associated with EAD treated surgically in our institution from 2010-2016. In our study, we only included cases treated via simultaneous TKA and corrective osteotomy (CO) and with a minimum follow-up period of three years. In terms of imaging, we determined the apex and angulation of the EAD as well as the modification of the mechanical parameters post-treatment. The pre- and postoperative clinical assessment was performed using the Knee Society Score (KSS). RESULTS: Ten patients (10 knees) underwent combined surgery (simultaneous TKA and CO). The mean age was 67.7 years and the mean follow-up period was 49.2 months. The mechanical parameters were consistently corrected in the post-operative period. The mechanical axis deviation (MAD) shifted from a mean value of 6.9 cm to 0.45 cm and the joint line was rendered horizontal in all cases. In none of the cases did the bone resection affect the insertion of the colateral ligaments. The mean KSS value improved from 32.3 points preoperatively to 79.4 postoperatively. There were no major complications, but there were two planning errors that did not impact upon the end result. CONCLUSIONS: In severe associated KOA and EAD, the combined surgical treatment proposed achieves in one stage an effective anatomical and mechanical correction which is crucial to optimise clinical results and implant durability. The surgery is complex and requires careful planning. LEVEL OF EVIDENCE: Level IV Case series.

Interaction between angiotensin-converting enzyme gene rs4343 polymorphism, environment factors, and angiotensin II level on susceptibility to knee osteoarthritis.

OBJECTIVES: Osteoarthritis (OA) is a complex multifactorial disease. The association of knee OA risk with ACE gene rs4343 polymorphism, gene environment synergistic effect, and angiotensin II serum level has not been previously examined. Therefore, we investigate the ACE gene rs4343 polymorphism in knee OA, and its association with severity of knee OA, and angiotensin II serum level. METHODS: Using a case-control design, we recruited 200 subjects (100 cases and 100 controls) and all were subjected to genotyping of rs4343 SNP by real-time polymerase chain reaction and assay of serum angiotensin II level by ELISA. RESULTS: G containing genotypes (AG and GG) and G allele frequencies of the ACE rs4343 polymorphism were significantly higher in the case group than that in the control group. There was significant association between ACE rs4343 genotypes and risk of knee OA under the following genetic inheritance models: GG vs. AA (P=0.003), AA vs. GG/AG (P=0.014), AG/AA vs. GG (P=0.037), and G vs. A (P<0.001). Stratified analyses showed ACE rs4343 polymorphism was evidently associated with a significantly increased risk of knee OA among those had BMI≥25% (adjusted OR=3.016; 95% CI 1.052-8.648; P=0.040). Additionally, knee OA patients with GG genotype had greater knee specific WOMAC index, Kellgren score, and serum angiotensin II level than those with AA or GA genotypes. CONCLUSION: The investigated polymorphism in the ACE gene rs4343 may reflect the risk and severity of knee OA in the Egyptian population, particularly with the GG genotype. The interaction between ACE gene rs4343 polymorphism and obesity further increased the risk of knee OA. Moreover, the higher angiotensin II level may be involved in the pathogenesis of knee OA.

Ejercicio terapéutico en la disminución del dolor en pacientes con artrosis de rodilla grado 1: revisión sistemática / Therapeutic exercise to reduce pain in patients with grade 1 knee arthrosis: systematic review / Exercício terapêutico para reduzir a dor em pacientes com artrose grau 1 do joelho: revisão sistemática

La artrosis de rodilla grado 1 es un problema frecuente a escala mundial. La fisioterapia se presenta como una alternativa prometedora para el tratamiento conservador de esta patología, ya que reduce eficazmente la artralgia. Objetivo. Describir la eficacia de los ejercicios terapéuticos para aliviar el dolor en la artrosis de rodilla grado I. Metodología. Se trata de una revisión sistemática, que abarcó una búsqueda exhaustiva en varias bases de datos como Pubmed, Scielo y Elsevier. Los criterios de búsqueda incluyeron ensayos de control aleatorios, experimentales y cuasiexperimentales realizados entre los años 2017 y 2023. Resultados. De un total de 82 documentos se excluyeron 40 al ser estudios secundarios. Posteriormente, se excluyeron 21 estudios adicionales debido a la escasa relación entre las variables del estudio y a su falta de disponibilidad. Finalmente, se seleccionaron 21 artículos que cumplieron con los criterios de evaluación de calidad metodológica mediante la escala CRF-QS. Para evaluar el dolor, la rigidez, la funcionalidad y la calidad de vida, se utilizaron escalas como EVA, NPRS, WOMAC y OXFORD. Los ejercicios isocinéticos resultaron ser los más efectivos, ya que demostraron un aumento de la fuerza y el grosor del cartílago articular, lo que resultó en una disminución de las puntuaciones de EVA de 8,05 a 3,75. Conclusión. El ejercicio terapéutico supervisado centrado en el fortalecimiento de las extremidades inferiores ha demostrado ser una alternativa efectiva para el tratamiento conservador de la artrosis de rodilla grado I. Este enfoque alivia eficazmente el dolor, mejora la calidad de vida e incluso puede detener la progresión de la enfermedad.

Grade 1 knee osteoarthritis is a common problem worldwide. Physiotherapy is presented as a promising alternative for the conservative treatment of this pathology, since it effectively reduces arthralgia. Aim. To describe the effectiveness of therapeutic exercises to relieve pain in grade I knee osteoarthritis. Methodology. This is a systematic review, which included an exhaustive search in several databases such as Pubmed, Scielo and Elsevier. Search criteria included randomized, experimental and quasi-experimental control trials conducted between the years 2017 and 2023. Results. Of a total of 82 documents, 40 were excluded as they were secondary studies. Subsequently, 21 additional studies were excluded due to poor relationships between study variables and lack of availability. Finally, 21 articles were selected that met the methodological quality evaluation criteria using the CRF-QS scale. To evaluate pain, stiffness, functionality and quality of life, scales such as VAS, NPRS, WOMAC and OXFORD were used. Isokinetic exercises were found to be the most effective, demonstrating an increase in articular cartilage strength and thickness, resulting in a decrease in VAS scores from 8.05 to 3.75. Conclusion. Supervised therapeutic exercise focused on strengthening the lower extremities has been shown to be an effective alternative to the conservative treatment of grade I knee osteoarthritis. This approach effectively relieves pain, improves quality of life, and may even stop the progression of osteoarthritis. disease.

A osteoartrite do joelho grau 1 é um problema comum em todo o mundo. A fisioterapia apresenta-se como uma alternativa promissora para o tratamento conservador desta patologia, uma vez que reduz eficazmente a artralgia. Mirar. Descrever a eficácia dos exercícios terapêuticos no alívio da dor na osteoartrite de joelho grau I. Metodologia. Trata-se de uma revisão sistemática, que incluiu uma busca exaustiva em diversas bases de dados como Pubmed, Scielo e Elsevier. Os critérios de pesquisa incluíram ensaios de controle randomizados, experimentais e quase-experimentais realizados entre os anos de 2017 e 2023. Resultados. De um total de 82 documentos, 40 foram excluídos por se tratarem de estudos secundários. Posteriormente, 21 estudos adicionais foram excluídos devido às más relações entre as variáveis do estudo e à falta de disponibilidade. Por fim, foram selecionados 21 artigos que atenderam aos critérios de avaliação da qualidade metodológica pela escala CRF-QS. Para avaliar dor, rigidez, funcionalidade e qualidade de vida foram utilizadas escalas como VAS, NPRS, WOMAC e OXFORD. Os exercícios isocinéticos foram considerados os mais eficazes, demonstrando um aumento na força e espessura da cartilagem articular, resultando em uma diminuição nos escores VAS de 8,05 para 3,75. Conclusão. O exercício terapêutico supervisionado focado no fortalecimento das extremidades inferiores tem se mostrado uma alternativa eficaz ao tratamento conservador da osteoartrite do joelho grau I. Esta abordagem alivia eficazmente a dor, melhora a qualidade de vida e pode até interromper a progressão da osteoartrite.

Análisis de periodicidad de reinyección en gonartrosis con distintos tipos de ácidos hialurónicos / Analysis of reinjection periodicity in knee osteoarthritis with different types of hyaluronic acids

Objetivo: Evaluación de la periodicidad de reinyección de ácido hialurónico (AH) en pacientes con gonartrosis. Objetivo secundario: relacionar el grado de artrosis con el tiempo entre infiltraciones y posible estudio por subgrupos entre los diferentes preparados comerciales. Diseño: Estudio observacional retrospectivo. Materiales y método: Revisión de historias clínicas y radiografías de los pacientes con gonartrosis tratados con AH intraarticular en el Servicio de Rehabilitación en el periodo entre enero de 2017 y junio de 2019. Variables: sociodemográficas, lateralidad, fecha del acto, grado de artrosis según Kellgren y Lawrence, AH utilizado, tiempo entre infiltraciones. Análisis estadístico mediante curvas de Kaplan-Meier considerando la reinfiltración como evento final y test de Kruskal Wallis para valores cuantitativos no paramétricos. Resultados: Analizamos 110 actos de infiltración en 67 pacientes: media de edad en momento de infiltración 72,12 años, 85,1% mujeres, 59,1% rodilla derecha. Cuatro tipos de AH: 33 casos al 1%; PM: 0,9 MDa (AH1); 12 al 1,5%; PM: 1,5 – 2 MDa (AH2), 42 al 2%; PM: 1,2 MDa (AH3) y 6 Hilano G-F20; PM: 6 MDa (AH4). En 17 ocasiones no se registró el ácido hialurónico utilizado (AH5). Se reinfiltró en 32 ocasiones (29,09%). Media de meses (Intervalo de Confianza [IC] 95%) entre infiltraciones: AH1 6,9 (5,7-8,16), AH2 12,5 (0- 35), AH3 9,3 (5,5- 13,1), AH4 5 (3 – 6,9). En dos casos en que no se pudo establecer el tipo de preparado infiltrado, el valor medio entre reinfiltraciones fue 8,5 (5,6- 11,4).No hubo resultados estadísticamente significativos al realizar un análisis comparativo el tipo de AH ni el grado de artrosis con el tiempo de reinfiltración. Conclusiones: En nuestro estudio se observa que el AH3 presentó un mayor tiempo entre infiltraciones con respecto a los otros tipos sin poder establecer diferencias significativas.(AU)

Objective: To evaluate the periodicity of hyaluronic acid (HA) reinjection in patients with knee osteoarthritis. Secondary aim: To relate the degree of arthrosis with the time between infiltrations and the possible study by subgroups between the different commercial preparations. Design: Retrospective observational study. Materials and method: Review of medical records and X-rays of patients with knee osteoarthritis that had been treated with intra-articular HA at the Rehabilitation Service in the period between January 2017 and June 2019. Variables: Socio-demographic, Laterality, Intervention Date, Degree of Arthrosis according to Kellgren and Lawrence, HA used, Time between filtrations. Statistical analysis carried out by Kaplan–Meier curves, taking into account the reinfiltration as final event, and Kruskal–Wallis test for non-parametric quantitative data. Results: We analysed 110 infiltration acts in 67 patients: average age at the time of infiltration 72.12 years, 85.1% women, 59.1% right knee. 4 types of HA: 33 cases at 1%. MW: 0.9MDa (HA1), 12 at 1.5%. MW: 1.5–2MDa (HA2), 42 at 2%. MW: 1.2MDa (HA3) and 6 Hylan G-F20. MW: 6MDa (HA4).We reinfiltrated in 31 occasions (28.2%). Average of months (IC 95%) between infiltrations: HA1 6.9 (5.7–8.16), HA2 12.5 (0–35), HA3 9.3 (5.5–13.1), HA4 5 (3–6.9). In 2 cases where it was not possible to establish the type of infiltrated formulations, the mean value between reinfiltrations was 8.5 (5.6–11.4)There were no statistically significant results by relating the HA type or the degree of arthrosis with the reinfiltration time. Conclusions: In our study, we observe that the HA3 presented a longer time between infiltrations in comparison with other types, with no possibility to detect significant differences.(AU)

[Analysis of reinjection periodicity in knee osteoarthritis with different types of hyaluronic acids]. / Análisis de periodicidad de reinyección en gonartrosis con distintos tipos de ácidos hialurónicos.

OBJECTIVE: To evaluate the periodicity of hyaluronic acid (HA) reinjection in patients with knee osteoarthritis. Secondary aim: To relate the degree of arthrosis with the time between infiltrations and the possible study by subgroups between the different commercial preparations. DESIGN: Retrospective observational study. MATERIALS AND METHOD: Review of medical records and X-rays of patients with knee osteoarthritis that had been treated with intra-articular HA at the Rehabilitation Service in the period between January 2017 and June 2019. VARIABLES: Socio-demographic, Laterality, Intervention Date, Degree of Arthrosis according to Kellgren and Lawrence, HA used, Time between filtrations. Statistical analysis carried out by Kaplan-Meier curves, taking into account the reinfiltration as final event, and Kruskal-Wallis test for non-parametric quantitative data. RESULTS: We analysed 110 infiltration acts in 67 patients: average age at the time of infiltration 72.12 years, 85.1% women, 59.1% right knee. 4 types of HA: 33 cases at 1%. MW: 0.9MDa (HA1), 12 at 1.5%. MW: 1.5-2MDa (HA2), 42 at 2%. MW: 1.2MDa (HA3) and 6 Hylan G-F20. MW: 6MDa (HA4). We reinfiltrated in 31 occasions (28.2%). Average of months (IC 95%) between infiltrations: HA1 6.9 (5.7-8.16), HA2 12.5 (0-35), HA3 9.3 (5.5-13.1), HA4 5 (3-6.9). In 2 cases where it was not possible to establish the type of infiltrated formulations, the mean value between reinfiltrations was 8.5 (5.6-11.4) There were no statistically significant results by relating the HA type or the degree of arthrosis with the reinfiltration time. CONCLUSIONS: In our study, we observe that the HA3 presented a longer time between infiltrations in comparison with other types, with no possibility to detect significant differences.

Embolización de arterias geniculares en pacientes con osteoartrosis de rodilla como alternativa de tratamiento del dolor. Una revisión sistemática / Embolization of genicular arteries in patients with knee osteoarthritis as an alternative for refractory pain treatment: A systematic review

Introducción: La embolización de arterias geniculares emerge como una técnica innovadora para el tratamiento del dolor refractario en pacientes con osteoartrosis (OA) de rodilla. Se exponen los datos disponibles sobre su eficacia en pacientes con OA de rodilla y dolor persistente, como tratamiento alternativo o asociado a tratamiento farmacológico.MétodosRevisión según estándares PRISMA® sobre embolización de arterias geniculares y OA de rodilla.ResultadosSe analizaron 13 publicaciones según criterios de inclusión, de un total de 63 estudios obteniendo datos de 914 pacientes. Las indicaciones de embolización se realizaron en pacientes con dolor crónico severo refractario a tratamiento conservador y con OA de rodilla moderada a severa. Solo se han reportado complicaciones menoresConclusiónLa embolización de arterias geniculares es una alternativa posible y potencialmente muy eficaz en el tratamiento del dolor articular crónico en pacientes con OA de rodilla, y sin complicaciones graves descritas. Todos los estudios concluyen a su favor en el tratamiento del dolor articular en estos pacientes. (AU)

Background: Genicular artery embolization emerges as an innovative technique described for the treatment of refractory pain in patients with knee osteoarthritis. This review summarizes the available data on the efficacy of genicular artery embolization in patients with knee osteoarthritis (OA) and refractory pain as an alternative treatment or associated with pharmacological treatment.MethodsReview according to PRISMA® standards on genicular artery embolization and knee osteoarthritis.ResultsThirteen publications out of a total of 63 studies reporting data from 914 patients were analyzed according to inclusion criteria. The indication of embolization was performed in patients with severe chronic pain refractory to conservative treatment and moderate-to-severe knee OA. Only minor complications have been reported.ConclusionGenicular artery embolization is a possible and potentially very effective alternative in the treatment of chronic refractory pain in patients with knee OA, without serious complications. All studies conclude in favor of embolization of the genicular arteries in the treatment of chronic refractory pain in patients with knee OA. (AU)

[Embolization of genicular arteries in patients with knee osteoarthritis as an alternative for refractory pain treatment: A systematic review]. / Embolización de arterias geniculares en pacientes con osteoartrosis de rodilla como alternativa de tratamiento del dolor. Una revisión sistemática.

BACKGROUND: Genicular artery embolization emerges as an innovative technique described for the treatment of refractory pain in patients with knee osteoarthritis. This review summarizes the available data on the efficacy of genicular artery embolization in patients with knee osteoarthritis (OA) and refractory pain as an alternative treatment or associated with pharmacological treatment. METHODS: Review according to PRISMA® standards on genicular artery embolization and knee osteoarthritis. RESULTS: Thirteen publications out of a total of 63 studies reporting data from 914 patients were analyzed according to inclusion criteria. The indication of embolization was performed in patients with severe chronic pain refractory to conservative treatment and moderate-to-severe knee OA. Only minor complications have been reported. CONCLUSION: Genicular artery embolization is a possible and potentially very effective alternative in the treatment of chronic refractory pain in patients with knee OA, without serious complications. All studies conclude in favor of embolization of the genicular arteries in the treatment of chronic refractory pain in patients with knee OA.

Tratamiento de la artrosis de rodilla con células mesenquimales estromales expandidas: revisión sistemática de la literatura / Expanded Mesenchymal Stromal Cells in Knee Osteoarthritis: A Systematic Literature Review

Objetivo: Analizar la eficacia y la seguridad de los implantes de células mesenquimales estromales expandidas (MSCs, por sus siglas en inglés) en la artrosis de rodilla. Métodos: Revisión sistemática de la literatura. Estrategia de búsqueda en Medline, Embase y Cochrane Library hasta febrero del 2018. Inclusión: artrosis de rodilla (II-IV Kellgren); inyección intra-articular de MSCs; ensayos controlados aleatorizados (ECA) y ensayos clínicos cuasi-experimentales (ECC)≥6 meses y N≥10. Resultados: De 252 artículos identificados, se incluyeron 3 ECA y 6 ECC (N=169). El 60% de los pacientes mejoraron clínicamente y el 50% estructuralmente hasta 2 años después del implante. El beneficio máximo se alcanzó al año con dosis ≥40×106 MSCs. La intervención fue bien tolerada, igualmente segura en implantes alogénicos y autólogos. Conclusiones: Las MSCs intra-articulares son seguras. La baja calidad de la evidencia analizada no admite conclusiones sobre la eficacia, pero prueba un fundamento para su uso en la artrosis como modificador de síntoma y de estructura que debe ser constatado en ensayos de alta calidad.(AU)

Objective: To analyse the efficacy and safety of intra-articular injection of expanded Mesenchymal Stromal Cells (MSCs) in knee osteoarthritis. Methods: Systematic Literature Review. A pre-defined search strategy was run in Medline, Embase and Cochrane Library until February 2018. Inclusion criteria: knee osteoarthritis (grades II-IV Kellgren-Lawrence); intra-articular injection of MSCs (without surgical co-treatments); Randomized Controlled Trials (RCTs) or Quasi-experimental Clinical Trials (QCTs) N≥10 and ≥6 months of follow-up were included. Evidence was assigned according to the Scottish Intercollegiate Guidelines Network (SIGN). Results: The search identified 252 articles. Nine proof-of-concept trials (3 RCTs, 6 QCTs) were included (N=169). Evidence showed clinical improvement in 60% of patients. Structural benefit was reported in half of patients. Clinical benefit was observed from the 3rd month and structural improvement from the 6th. All studies reported maximum clinical and structural benefit a year following the implant. This benefit was sustained for up to 24 months. Studies with doses ≥40×106 showed more consistent clinical and structural benefits than those with lower doses. No systemic adverse reactions were reported. The most common adverse effect was pain and/or inflammation in the puncture area (13-53%). The use of donor cells was as safe as autologous implants. Conclusions: Intra-articular implants of MSCs seem to be safe with no serious adverse effects. Low-quality evidence precludes conclusions regarding efficacy in this review. However, the clinical and structural benefits observed provide a rationale for using expanded MSCs implants in osteoarthritis patients. High-quality evidence trials are needed to further determine best protocols to maximize clinical and structural improvement.(AU)

Osteoprotegerin changes in saliva and serum of patients with knee osteoarthritis / Cambios de osteoprotegerina en saliva y suero de pacientes con osteoartritis de rodilla

Objective: The scope of this study was to assess salivary and serum osteoprotegerin (OPG) levels in knee osteoarthritis (OA). Methods: Serum and saliva OPG levels of 30 knee OA and 30 matched healthy controls in this cross-sectional study was assessed by ELISA. Knee pain was assessed by WOMAC. Data were analyzed by Student's t-test, Spearman correlation test and ROC. Results: The mean serum but not saliva OPG level was lower in knee OA than that of the healthy group. WOMAC negatively correlated with serum OPG (r = −0.501; P = 0.000). The serum OPG cutoff value was 237.5 pg/ml for the diagnosis of knee OA. Conclusions: As serum OPG was lower in knee OA and negatively correlated with WOMAC, it seems that detection of OPG in serum but not in saliva may be a probable marker to the diagnosis of knee OA. Key messages: Osteoprotegerin decreases in knee osteoarthritis.(AU)

Objetivo: El alcance de este estudio fue evaluar los niveles de osteoprotegerina (OPG) salival y sérica en la osteoartritis de rodilla (OA). Métodos: Los niveles de OPG en suero y saliva de 30 OA y 30 controles sanos emparejados en este estudio transversal se evaluaron mediante ELISA. El dolor de rodilla fue evaluado por The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Los datos se analizaron mediante la prueba t de Student, la prueba de correlación de Spearman y receiver operating characteristic (ROC). Resultados: El nivel medio de OPG en suero, pero no en saliva fue menor en la artrosis de rodilla que en el grupo sano. WOMAC se correlacionó negativamente con la OPG sérica (r = −0,501; p = 0,000). El valor de corte de OPG sérico fue de 237,5 pg/mL para el diagnóstico de OA de rodilla. Conclusiones: Como la OPG sérica fue más baja en la artrosis de rodilla y se correlacionó negativamente con WOMAC, parece que la detección de OPG en suero, pero no en la saliva puede ser un marcador probable para el diagnóstico de artrosis de rodilla. Mensajes clave: La osteoprotegerina disminuye en la osteoartritis de rodilla.(AU)

Cambios de osteoprotegerina en saliva y suero de pacientes con osteoartritis de rodilla / Osteoprotegerin changes in saliva and serum of patients with knee osteoarthritis

Objetivo: El alcance de este estudio fue evaluar los niveles de osteoprotegerina (OPG) salival y sérica en la osteoartritis de rodilla (OA). Métodos: Los niveles de OPG en suero y saliva de 30 OA y 30 controles sanos emparejados en este estudio transversal se evaluaron mediante ELISA. El dolor de rodilla fue evaluado por The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Los datos se analizaron mediante la prueba t de Student, la prueba de correlación de Spearman y receiver operating characteristic (ROC). Resultados: El nivel medio de OPG en suero, pero no en saliva fue menor en la artrosis de rodilla que en el grupo sano. WOMAC se correlacionó negativamente con la OPG sérica (r = −0,501; p = 0,000). El valor de corte de OPG sérico fue de 237,5 pg/mL para el diagnóstico de OA de rodilla. Conclusiones: Como la OPG sérica fue más baja en la artrosis de rodilla y se correlacionó negativamente con WOMAC, parece que la detección de OPG en suero, pero no en la saliva puede ser un marcador probable para el diagnóstico de artrosis de rodilla. Mensajes clave: La osteoprotegerina disminuye en la osteoartritis de rodilla.(AU)

Objective: The scope of this study was to assess salivary and serum osteoprotegerin (OPG) levels in knee osteoarthritis (OA). Methods: Serum and saliva OPG levels of 30 knee OA and 30 matched healthy controls in this cross-sectional study was assessed by ELISA. Knee pain was assessed by WOMAC. Data were analyzed by Student's t-test, Spearman correlation test and ROC. Results: The mean serum but not saliva OPG level was lower in knee OA than that of the healthy group. WOMAC negatively correlated with serum OPG (r = −0.501; P = 0.000). The serum OPG cutoff value was 237.5 pg/ml for the diagnosis of knee OA. Conclusions: As serum OPG was lower in knee OA and negatively correlated with WOMAC, it seems that detection of OPG in serum but not in saliva may be a probable marker to the diagnosis of knee OA. Key messages: Osteoprotegerin decreases in knee osteoarthritis.(AU)

Expanded Mesenchymal Stromal Cells in knee osteoarthritis: A systematic literature review.

OBJECTIVE: To analyse the efficacy and safety of intra-articular injection of expanded Mesenchymal Stromal Cells (MSCs) in knee osteoarthritis. METHODS: Systematic Literature Review. A pre-defined search strategy was run in Medline, Embase and Cochrane Library until February 2018. INCLUSION CRITERIA: knee osteoarthritis (grades II-IV Kellgren-Lawrence); intra-articular injection of MSCs (without surgical co-treatments); Randomized Controlled Trials (RCTs) or Quasi-experimental Clinical Trials (QCTs) N ≥ 10 and ≥6 months of follow-up were included. Evidence was assigned according to the Scottish Intercollegiate Guidelines Network (SIGN). RESULTS: The search identified 252 articles. Nine proof-of-concept trials (3 RCTs, 6 QCTs) were included (N = 169). Evidence showed clinical improvement in 60% of patients. Structural benefit was reported in half of patients. Clinical benefit was observed from the 3rd month and structural improvement from the 6th. All studies reported maximum clinical and structural benefit a year following the implant. This benefit was sustained for up to 24 months. Studies with doses ≥40 × 106 showed more consistent clinical and structural benefits than those with lower doses. No systemic adverse reactions were reported. The most common adverse effect was pain and/or inflammation in the puncture area (13-53%). The use of donor cells was as safe as autologous implants. CONCLUSIONS: Intra-articular implants of MSCs seem to be safe with no serious adverse effects. Low-quality evidence precludes conclusions regarding efficacy in this review. However, the clinical and structural benefits observed provide a rationale for using expanded MSCs implants in osteoarthritis patients. High-quality evidence trials are needed to further determine best protocols to maximize clinical and structural improvement.

Osteoprotegerin changes in saliva and serum of patients with knee osteoarthritis. / Cambios de osteoprotegerina en saliva y suero de pacientes con osteoartritis de rodilla.

OBJECTIVE: The scope of this study was to assess salivary and serum osteoprotegerin (OPG) levels in knee osteoarthritis (OA). METHODS: Serum and saliva OPG levels of 30 knee OA and 30 matched healthy controls in this cross-sectional study was assessed by ELISA. Knee pain was assessed by WOMAC. Data were analyzed by Student's t-test, Spearman correlation test and ROC. RESULTS: The mean serum but not saliva OPG level was lower in knee OA than that of the healthy group. WOMAC negatively correlated with serum OPG (r = -0.501; P = 0.000). The serum OPG cutoff value was 237.5 pg/ml for the diagnosis of knee OA. CONCLUSIONS: As serum OPG was lower in knee OA and negatively correlated with WOMAC, it seems that detection of OPG in serum but not in saliva may be a probable marker to the diagnosis of knee OA. KEY MESSAGES: Osteoprotegerin decreases in knee osteoarthritis.

Prevalencia de artrosis sintomática en España: Estudio EPISER2016 / Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study

Introducción: La Sociedad Española de Reumatología elaboró en el año 2000 el estudio EPISER2000 para conocer la prevalencia de la artrosis y otras enfermedades reumáticas en España. Los cambios sociodemográficos y en los hábitos de vida ocurridos en los últimos años en España justifican actualizar los datos de las enfermedades reumáticas (EPISER2016). Objetivo: Estimar la prevalencia de artrosis sintomática de columna cervical, columna lumbar, cadera, rodilla y mano, en población adulta en España. Material y métodos: Estudio transversal de base poblacional. Se realizó un muestreo aleatorizado polietápico estratificado y por conglomerados. Los participantes fueron contactados por teléfono para cumplimentar un cuestionario de cribado de artrosis. El reumatólogo confirmaba o descartaba el diagnóstico. Se utilizaron los criterios-clínicos-ACR para diagnosticar artrosis de manos y los criterios clínico-radiológicos-ACR para diagnosticar la artrosis de rodilla y cadera. Resultados: La prevalencia de artrosis en España en una o más de las localizaciones estudiadas fue de 29,35%. La prevalencia de artrosis-cervical fue del 10,10% y de artrosis-lumbar del 15,52%. Ambas son más frecuentes en mujeres y a mayor edad, así como en personas con niveles de estudios bajos y obesidad. La prevalencia de artrosis de cadera fue del 5,13% y la de artrosis de rodilla del 13,83%; estas se asocian con el sexo femenino, sobrepeso y obesidad, menor frecuencia en nivel de estudios alto y con la edad. La prevalencia de la artrosis de mano fue del 7,73%. Es más frecuente en mujeres, obesas, con bajo nivel de estudios y mayor edad. Conclusiones: El estudio EPISER2016 es el primero que analiza la prevalencia de artrosis sintomática en 5 localizaciones (columna cervical, lumbar, rodilla, cadera y manos) en España. La artrosis de la columna lumbar es la más prevalente.(AU)

Introduction: The Spanish Society of Rheumatology carried out the EPISER2000 study in 2000 to determine the prevalence of osteoarthritis and other rheumatic diseases in the Spanish population. Recent sociodemographic changes and lifestyle habits in Spain justified updating the epidemiological data on osteoarthritis and other rheumatic diseases (EPISER2016-study). Objective: To estimate the prevalence of symptomatic osteoarthritis of the cervical spine, lumbar spine, hip, knee and hand in the adult population in Spain. Material and methods: Cross-sectional population-based study. A multistage and stratified random cluster sampling was carried out. The participants were contacted by telephone to complete an osteoarthritis screening questionnaire. A rheumatologist confirmed or discarded the diagnosis. The ACR-clinical-criteria were used to diagnose hand-osteoarthritis and the ACR-clinical-radiological criteria to diagnose knee- and hip-osteoarthritis. To estimate the prevalence and its 95% confidence interval, weights were calculated according to the probability of selection in each of the sampling stages. Results: The prevalence of osteoarthritis in Spain in one or more of the locations studied was 29.35%. The prevalence of cervical-osteoarthritis was 10.10% and of lumbar-osteoarthritis 15.52%. Both are more frequent in women and at older ages, as well as in people with low levels of education and obesity. The prevalence of hip-osteoarthritis was 5.13%, that of knee-osteoarthritis 13.83%, these are associated with female sex, overweight and obesity. The prevalence of hand osteoarthritis was 7.73%. It is more frequent in women, who are obese, with a low educational level and who are older. Conclusion: The EPISER2016 study is the first to analyse the prevalence of symptomatic osteoarthritis in 5 locations (cervical, lumbar, knee, hip and hands) in Spain. Lumbar spine osteoarthritis is the most prevalent.(AU)

Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study.

INTRODUCTION: The Spanish Society of Rheumatology carried out the EPISER2000 study in 2000 to determine the prevalence of osteoarthritis and other rheumatic diseases in the Spanish population. Recent sociodemographic changes and lifestyle habits in Spain justified updating the epidemiological data on osteoarthritis and other rheumatic diseases (EPISER2016-study). OBJECTIVE: To estimate the prevalence of symptomatic osteoarthritis of the cervical spine, lumbar spine, hip, knee and hand in the adult population in Spain. MATERIAL AND METHODS: Cross-sectional population-based study. A multistage and stratified random cluster sampling was carried out. The participants were contacted by telephone to complete an osteoarthritis screening questionnaire. A rheumatologist confirmed or discarded the diagnosis. The ACR-clinical-criteria were used to diagnose hand-osteoarthritis and the ACR-clinical-radiological criteria to diagnose knee- and hip-osteoarthritis. To estimate the prevalence and its 95% confidence interval, weights were calculated according to the probability of selection in each of the sampling stages. RESULTS: The prevalence of osteoarthritis in Spain in one or more of the locations studied was 29.35%. The prevalence of cervical-osteoarthritis was 10.10% and of lumbar-osteoarthritis 15.52%. Both are more frequent in women and at older ages, as well as in people with low levels of education and obesity. The prevalence of hip-osteoarthritis was 5.13%, that of knee-osteoarthritis 13.83%, these are associated with female sex, overweight and obesity. The prevalence of hand osteoarthritis was 7.73%. It is more frequent in women, who are obese, with a low educational level and who are older. CONCLUSION: The EPISER2016 study is the first to analyse the prevalence of symptomatic osteoarthritis in 5 locations (cervical, lumbar, knee, hip and hands) in Spain. Lumbar spine osteoarthritis is the most prevalent.

Tendencia temporal y evaluación demográfica de hospitalizaciones por osteoartritis / Temporal trends and demographic evaluation of hospitalizations due to osteoarthritis

OBJETIVO: Describir la tendencia temporal de osteoartritis (OA) según egresos hospitalarios considerando ubicación anatómica, distribución por sexo, edad, condiciones más frecuentes, y ubicación geográfica en Chile entre los años 2012 y 2018. METODOLOGÍA: Estudio descriptivo, retrospectivo, poblacional, que analizó las bases de datos públicas del Departamento de Estadísticas e Información en Salud (DEIS) del Ministerio de Salud de Chile, en particular los registros con codificación de M15 a M19. Se calcularon las tasas por 100 mil egresos hospitalarios, así como también el porcentaje de OA según las categorías analizadas. RESULTADOS: Se encontraron 11.622.605 egresos hospitalarios entre 2012 y 2018. El número total de egresos hospitalarios por OA fue de 78.700. Se observó que la distribución por sexo fue similar a lo largo de los años ( 40% y 60% en hombres y mujeres, respectivamente). El rango de edad más afectado fue el de 65 a 79 años, cuya tasa promedio fue de 2.046 por 100 mil egresos; además, fue el grupo que presentó el mayor aumento (60%) en su tasa de 2012 a 2018. La Región Metropolitana (291,7 egresos) y de Valparaíso (89,6 egresos) presentaron las tasas más altas. La cadera (56,6%) y la rodilla (31%) fueron las ubicaciones más frecuentes de casos de OA, con distribución similar por sexo, edad y geografía en comparación a los egresos totales por OA. CONCLUSIONES: Los egresos hospitalarios por OA en Chile aumentaron entre 2012 y 2018, preferencialmente en casos de OA en las articulaciones de cadera y rodilla en el grupo de mujeres de edad avanzada de la zona centro del país. NIVEL DE EVIDENCIA: Estudio descriptivo.

OBJECTIVE: To describe the temporal trends of osteoathritis (OA) according to hospital discharges considering anatomical location, distribution by gender, age, more frequent conditions, and geographic location in Chile between 2012 and 2018. METHODOLOGY: A retrospective, descriptive and population study which analyzed the public databases of the Department of Health Statistics and Information (Departamento de Estadísticas e Información en Salud, DEIS, in Spanish) of the Ministry of Health of Chile, in particular the records with codes M15 through M19. Rates per 100 thousand hospital discharges were calculated, as well as the percentage of OA according to the categories analyzed. RESULTS: A total of 11,622,605 hospital discharges were found between 2012 and 2018. The total number of hospital discharges due to OA was of 78,700. The distribution by gender was similar over the years ( 40% and 60% among men and women respectively). Adults aged between 65 and 79 years were the most affected, and their average rate was of 2,046 per 100 thousand discharges. It was also the group that presented the highest increase (60%) in rate from 2012 to 2018. The Metropolitan Region (291.7 discharges) and Valparaíso (89.6 discharges) presented the highest rates in Chile. The hip (56.6%) and knee (31%) were the most frequent locations of OA, which presented similar distribution by gender, age and geography when compared with the total discharges due to OA. CONCLUSIONS: Hospital discharges due to OA in Chile increased between 2012 and 2018, preferentially in cases of hip and knee-joint OA in the group of elderly women in the central area of the country. LEVEL OF EVIDENCE: Descriptive study.

Epidemiología, repercusión clínica y objetivos terapéuticos en la artrosis / Epidemiology, clinical impact and therapeutic objectives in osteoarthritis

La artrosis es uno de los principales problemas de salud en todos los países, más prevalente en los países desarrollados probablemente debido a factores como el aumento de la longevidad, el sedentarismo y la obesidad. Las estadísticas de salud muestran un continuo crecimiento de su incidencia e importancia global sobre la discapacidad. El objetivo es analizar y sintetizar el problema de salud que representa la artrosis, aportando datos epidemiológicos de prevalencia, repercusión clínica, pérdida de calidad de vida y costes que ocasiona. Se muestran los objetivos terapéuticos que son clínicamente relevantes, tanto aquellos preventivos o modificables como los cofactores que modifican el grado de respuesta a los mismos. Se trata de una revisión sistemática de la literatura de los últimos 10 años en la base de datos PubMed para términos “Mesh” relacionados con epidemiología, prevención, tratamiento y resultados informados por el paciente para artrosis de rodilla y cadera. Hemos encontrado una gran variabilidad en los resultados epidemiológicos comunicados, consecuencia de los diferentes criterios de inclusión y metodología de los estudios, mostrando prevalencias del 83 % en estudios con resonancia magnética en pacientes asintomáticos hasta el 3,8 % de artrosis sintomática de rodilla en estudios poblacionales en adultos. La edad, el sexo femenino, la etnia y la obesidad parecen ser los factores más importantes relacionados con la enfermedad. Otros factores como los genéticos, biomecánicos (consecuencia de lesiones deportivas y ocupacionales), hormonales, el síndrome metabólico y el sedentarismo han mostrado una clara asociación con la enfermedad. El coste directo e indirecto de la artrosis representa entre el 0,5 y el 1 % del PIB, según países. La revisión de los objetivos terapéuticos muestra que los pacientes perciben como cambios mínimamente relevantes aquellas terapias...(AU)

Osteoarthritis is one of the main health problems in all countries, most prevalent in developed countries, probably due to factors such as increased longevity, a sedentary lifestyle and obesity. Health statistics show a continued growth in its overall impact and importance on disability. The objective is to analyze and synthesize the health problem posed by osteoarthritis, providing epidemiological data on prevalence, clinical impact, loss of quality of life and costs it causes. Those therapeutic objectives that are clinically relevant, will be shown, both those preventive and modifiable as well as the cofactors that modify the degree of response to them. Systematic review of the literature of the last 10 years in the Pubmed database for terms "Mesh" related to epidemiology, prevention, treatment, and patient reported outcomes for knee and hip osteoarthritis.We have found great variability in reported epidemiological results, a consequence of the different inclusion criteria and methodology of studies, showing prevalence of 83% in Magnetic Resonance studies with asymptomatic patients up to 3.8% of symptomatic knee osteoarthritis in adult population studies. Age, female sex, ethnicity and obesity seem like the most important factors related to the disease. Other factors such as genetics, biomechanics resulting from sports and occupational injuries, hormonal, metabolic syndrome and sedentary lifestyles have shown a clear association with the disease. The direct and indirect cost of osteoarthritis represents between 0.5 and 1% of GDP, according to countries. The review of therapeutic goals shows that patients perceive as minimally relevant changes those therapies that achieve a decrease of 2 points or 33 % on the VAS Analypain scale, but these cut-off points will depend on the affected joint and the severity of the initial pain...(AU)

Expanded Mesenchymal Stromal Cells in Knee Osteoarthritis: A Systematic Literature Review. / Tratamiento de la artrosis de rodilla con células mesenquimales estromales expandidas: revisión sistemática de la literatura.

OBJECTIVE: To analyse the efficacy and safety of intra-articular injection of expanded Mesenchymal Stromal Cells (MSCs) in knee osteoarthritis. METHODS: Systematic Literature Review. A pre-defined search strategy was run in Medline, Embase and Cochrane Library until February 2018. INCLUSION CRITERIA: knee osteoarthritis (grades II-IV Kellgren-Lawrence); intra-articular injection of MSCs (without surgical co-treatments); Randomized Controlled Trials (RCTs) or Quasi-experimental Clinical Trials (QCTs) N≥10 and ≥6 months of follow-up were included. Evidence was assigned according to the Scottish Intercollegiate Guidelines Network (SIGN). RESULTS: The search identified 252 articles. Nine proof-of-concept trials (3 RCTs, 6 QCTs) were included (N=169). Evidence showed clinical improvement in 60% of patients. Structural benefit was reported in half of patients. Clinical benefit was observed from the 3rd month and structural improvement from the 6th. All studies reported maximum clinical and structural benefit a year following the implant. This benefit was sustained for up to 24 months. Studies with doses ≥40×106 showed more consistent clinical and structural benefits than those with lower doses. No systemic adverse reactions were reported. The most common adverse effect was pain and/or inflammation in the puncture area (13-53%). The use of donor cells was as safe as autologous implants. CONCLUSIONS: Intra-articular implants of MSCs seem to be safe with no serious adverse effects. Low-quality evidence precludes conclusions regarding efficacy in this review. However, the clinical and structural benefits observed provide a rationale for using expanded MSCs implants in osteoarthritis patients. High-quality evidence trials are needed to further determine best protocols to maximize clinical and structural improvement.

Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study. / Prevalencia de artrosis sintomática en España: Estudio EPISER2016.

INTRODUCTION: The Spanish Society of Rheumatology carried out the EPISER2000 study in 2000 to determine the prevalence of osteoarthritis and other rheumatic diseases in the Spanish population. Recent sociodemographic changes and lifestyle habits in Spain justified updating the epidemiological data on osteoarthritis and other rheumatic diseases (EPISER2016-study). OBJECTIVE: To estimate the prevalence of symptomatic osteoarthritis of the cervical spine, lumbar spine, hip, knee and hand in the adult population in Spain. MATERIAL AND METHODS: Cross-sectional population-based study. A multistage and stratified random cluster sampling was carried out. The participants were contacted by telephone to complete an osteoarthritis screening questionnaire. A rheumatologist confirmed or discarded the diagnosis. The ACR-clinical-criteria were used to diagnose hand-osteoarthritis and the ACR-clinical-radiological criteria to diagnose knee- and hip-osteoarthritis. To estimate the prevalence and its 95% confidence interval, weights were calculated according to the probability of selection in each of the sampling stages. RESULTS: The prevalence of osteoarthritis in Spain in one or more of the locations studied was 29.35%. The prevalence of cervical-osteoarthritis was 10.10% and of lumbar-osteoarthritis 15.52%. Both are more frequent in women and at older ages, as well as in people with low levels of education and obesity. The prevalence of hip-osteoarthritis was 5.13%, that of knee-osteoarthritis 13.83%, these are associated with female sex, overweight and obesity. The prevalence of hand osteoarthritis was 7.73%. It is more frequent in women, who are obese, with a low educational level and who are older. CONCLUSION: The EPISER2016 study is the first to analyse the prevalence of symptomatic osteoarthritis in 5 locations (cervical, lumbar, knee, hip and hands) in Spain. Lumbar spine osteoarthritis is the most prevalent.

Inyección Intraarticular Única de Ácido Hialurónico en la Artrosis de Rodilla: Estudio Multicéntrico Prospectivo Abierto (ART-ONE 75) mediante Comparación Post-Hoc con Placebo.

INTRODUCCIÓN: La viscosuplementación del líquido sinovial mediante la inyección intraarticular (IA) de ácido hialurónico (AH) es un tratamiento sintomático ampliamente utilizado en la artrosis de rodilla (AR). Además de los productos diseñados para realizar inyecciones múltiples (normalmente de 3 a 5 inyecciones, en intervalos de 1 semana), se presta especial atención a los productos de una única inyección, ya que ofrecen ventajas específicas, como son un menor número de visitas al médico y de intervenciones invasivas con sus riesgos asociados. Sin embargo, aún existen dudas sobre la eficacia de estas inyecciones únicas, en comparación con los regímenes de inyecciones múltiples. MÉTODOS: Se realizó un estudio multicéntrico, abierto, prospectivo, post-mercado (ART-ONE 75) con el producto de inyección única ARTHRUM 2,5% (3 ml, 75 mg AH), en 214 pacientes que sufrían de AR. Los pacientes fueron seguidos en D30, D60, D120 y D180 (días). El perfil promedio de los pacientes en el momento de la inclusión fue de 62,9 años, 56% mujeres, grados I-III de Kellgren-Lawrence (46% KL III), IMC de 27,2 kg/m2 y 4 años desde el diagnóstico de AR. Se realizó una comparación post-hoc con una inyección IA única de placebo (326 pacientes, agrupados de 3 estudios ECA), que proporcionaron un perfil de paciente similar. RESULTADOS: el criterio principal fue la variación desde el inicio de la puntuación de la escala WOMAC A (dolor, escala 0-100) en D60, que se redujo en 28,9 (17,4) para la población por intención de tratar (ITT, por sus siglas en inglés) (199 pacientes), 28,0 (17,8) para la población por protocolo (PP) en la inclusión (175 pacientes), y en 27,7 (16,8) para la población PP al finalizar (143 pacientes).Los criterios secundarios y accesorios incluyeron WOMAC A en otras ocasiones, WOMAC B (rigidez), WOMAC C (función), calidad de vida y discapacidad en cada momento de seguimiento. Todos los índices mejoraron significativamente y continuaron mejorando al final del estudio. La evaluación terapéutica en D180 mostró que más del 75% de los pacientes se encontraban satisfechos con la reducción del dolor, la mejora de la movilidad, y la reducción de analgésicos y AINE. El porcentaje de pacientes definidos como respondedores de OMERACT-OARSI fue superior al 86%, a partir de D60 y en adelante. La tolerancia general fue buena, sin que ocurriera ningún evento adverso grave. El resultado de la comparación post-hoc para la escala WOMAC A mostró un tamaño del efecto [IC 95%] desde TE = 0,33 [0,15; 0,51] en D60 a TE = 0,65 [0,45; 0,85] en D180 (p <0,001), frente a la inyección de placebo (solución salina), lo cual es un resultado clínicamente relevante a favor de ARTHRUM 2,5%. CONCLUSIÓN: El presente estudio confirma la eficacia clínica de una única inyección IA de 3 ml de solución de AH conteniendo 75 mg de AH nativo de alto PM (> 2 MDa).

Effect of chondroitin sulphate on synovitis of knee osteoarthritic patients. / Efecto del condroitín sulfato en la sinovitis de pacientes con artrosis de rodilla.

OBJECTIVE: To evaluate by ultrasonography the effect of chondroitin sulfate (CS) on synovitis in patients with knee osteoarthritis (KOA). To collaborate in the understanding of the biochemical mechanisms involved in the synovial inflammation process. METHODS: Randomized, single-blind, controlled trial involving 70 patients with primary KOA treated for 6 months with CS or acetaminophen (ACT). Evaluation of KOA status at baseline, 6 weeks, 3 and 6 months included: ultrasonography to assess synovitis (following the OMERACT expertise group definition), visual analogue scale and Lequesne index to measure pain and function, and ELISA to quantify inflammatory mediators in serum and synovial fluid. RESULTS: Synovitis presence was reduced by 50% in the CS group while a 123% increase was observed in ACT group. Conversely, patients without initial synovitis and treated with ACT reached 85.71% synovitis onset, but only 25% in CS group. Both therapies improved articular function, but only CS resulted in significant pain improvement at the end of the treatment. Changes in RANTES and UCN synovial fluid concentration were associated with CS treatment. CONCLUSIONS: Treatment with CS had a sustained beneficial effect, preventing synovitis onset or reducing its presence as well as reducing KOA symptoms. ACT ameliorated clinical symptoms but had no effect on inflammation. The CS anti-inflammatory effect could be related to the observed changes in RANTES and UCN concentration.